GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

obinutuzumab   Click here for help

GtoPdb Ligand ID: 6941

Synonyms: GA-101 | GA101 | Gazyva®
Approved drug Immunopharmacology Ligand
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class: Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

Bioactivity Comments
In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies rituximab and ofatumumab [3]. In vivo, obinutuzumab induces a strong antitumour effect [3].
However, we have been unable to find affinity data for this antibody from any open access source.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD20 (membrane-spanning 4-domains, subfamily A, member 1) Primary target of this compound Hs Antibody Binding - - - 1,4
⤷ [1,4]